Prostate最新文献

{"title":"Transcriptomic Signatures of Monocyte-Derived Macrophages Associate With Androgen Receptor Pathway Inhibitor Progression in Prostate Cancer.","authors":"Marina Nasrin Sharifi, Erika Heninger, Matthew Leeson Bootsma, Emma Elizabeth Recchia, Matthew Thomas Breneman, Amy Kristine Taylor, Shuang George Zhao, Aaron Matthew LeBeau, David Kosoff","doi":"10.1002/pros.70000","DOIUrl":"10.1002/pros.70000","url":null,"abstract":"<p><strong>Background: </strong>Androgen receptor pathway inhibitors (ARPIs) have significantly improved clinical outcomes for patients with metastatic prostate cancer (PC) but acquired ARPI resistance remains universal. Maximizing ARPI treatment duration is crucial to optimal clinical outcomes, but current clinical tools to detect acquired ARPI resistance, including serum Prostate Specific Antigen (PSA) and radiographic disease monitoring, are limited in both sensitivity and specificity. Since prostate cancer disease progression is associated with an increase in systemic inflammation, we hypothesized that circulating monocytes and monocyte-derived macrophages (MDMs) in patients with PC would express an increased pro-inflammatory phenotype in the context of disease progression.</p><p><strong>Methods: </strong>Monocytes and MDMs were isolated from peripheral blood samples from 16 patients with PC who were receiving ARPI therapies and performed transcriptomic and functional analysis both alone and in ex vivo coculture with prostate tumor cells utilizing a novel microscale coculture platform.</p><p><strong>Results: </strong>We identified a pro-inflammatory transcriptional signature in MDMs cultured with tumor cells that was associated with current, recent, and impending disease progression. Furthermore, we found that the pro-inflammatory phenotype of MDMs derived from patients with clinical progression was associated with paracrine anti-tumorigenic signaling that sensitized tumor cells to ARPI treatment in vitro. Finally, a transcriptional score generated from the MDM transcriptional signature of progressing patients could accurately identify current treatment response status as well as patients with recent/impending changes in response status.</p><p><strong>Conclusions: </strong>Disease progression in patients with prostate cancer receiving ARPI therapy is associated with a pro-inflammatory gene signature in peripheral monocyte-derived macrophages. We were able to develop a scoring signature based on this pro-inflammatory gene signature that has the potential to identify patients with recent and impending changes in disease response status that is not detectable using conventional disease assessment criteria. Further research will be needed to validate these findings.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"1168-1180"},"PeriodicalIF":2.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12268948/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144555869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Mediterranean Diet and Benign Prostatic Hyperplasia: A Pathway to Improved Urinary Health.","authors":"İsa Dağlı, Tuncel Uzel, Muhammed Zübeyr Canbolat, Aykut Demirci, Fatih Hızlı","doi":"10.1002/pros.70009","DOIUrl":"10.1002/pros.70009","url":null,"abstract":"<p><strong>Background: </strong>Lower urinary tract symptoms (LUTS) are highly prevalent among aging men and are often associated with benign prostatic hyperplasia (BPH), significantly impacting quality of life. The Mediterranean Diet (MedDiet), known for its anti-inflammatory and antioxidant properties, has been hypothesized to alleviate LUTS and improve urological health.</p><p><strong>Objective: </strong>This study aimed to evaluate the impact of adherence to the MedDiet on uroflowmetry (UFM) parameters and International Prostate Symptom Scores (IPSS) in patients presenting with LUTS.</p><p><strong>Methods: </strong>A prospective study was conducted including 400 patients divided into two groups: MedDiet adherent (AMD, n = 193) and non-adherent (NAMD, n = 207). Adherence was assessed using the Mediterranean Diet Adherence Screener (MEDAS). UFM parameters, post-void residual (PVR) volumes, and IPSS were recorded. Statistical analyses were performed to evaluate group differences and correlations.</p><p><strong>Results: </strong>AMD patients exhibited significantly higher Qmax (13.87 ± 0.21 vs. 12.08 ± 0.19, p < 0.001) and lower IPSS (median: 9 vs. 17, p < 0.001) compared to the NAMD group. No significant differences were observed in Qaverage, PVR, or body mass index (BMI) between groups. Positive correlations were noted between MEDAS scores and Qmax (r = 0.259, p < 0.001), while IPSS showed a strong negative correlation with MEDAS scores (r = -0.610, p < 0.001).</p><p><strong>Conclusion: </strong>Adherence to the MedDiet may be associated with improved urinary function and reduced LUTS severity in BPH patients. These findings suggest the potential of dietary interventions as part of a holistic approach to managing BPH.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"1222-1226"},"PeriodicalIF":2.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144576922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SBRT Boost in Prostate Cancer: Progress Made, Questions Remain.","authors":"Cem Onal, Aysenur Elmali, Birhan Demirhan, Ozan Cem Guler","doi":"10.1002/pros.24919","DOIUrl":"10.1002/pros.24919","url":null,"abstract":"","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"1155-1156"},"PeriodicalIF":2.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144144255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum Levels of Prostate Specific Antigen, Free PSA, [-2]proPSA, fPSA/tPSA Ratio, Prostate Health Index, and Glycosylation Patterns of Free PSA in Patients With Benign Prostatic Hyperplasia Pharmacotherapy: Limitations and Future Directions.","authors":"Yitong Weng, Bing Ji","doi":"10.1002/pros.70003","DOIUrl":"10.1002/pros.70003","url":null,"abstract":"","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"1248-1249"},"PeriodicalIF":2.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144369556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring Latent Prostate Cancer: A Forensic Autopsy Study in South India.","authors":"Ishvaria Sundaresan, Nallasivam Palanisamy, Radha Saraswathy","doi":"10.1002/pros.70010","DOIUrl":"10.1002/pros.70010","url":null,"abstract":"<p><strong>Background: </strong>Forensic autopsies offer a unique opportunity to study the natural history of prostate cancer (PCa), especially in individuals who had no prior diagnosis or long-term medical interventions. These examinations provide unbiased data on the true prevalence and progression of latent, asymptomatic prostate cancer. Unlike PSA screening-which often leads to overdiagnosis and unnecessary treatment-autopsy studies reveal clinically silent cases, particularly in older men. This prospective analysis was conducted to explore the prevalence and features of latent PCa in a South Indian population.</p><p><strong>Methods: </strong>A study was conducted at a primary hospital in Vellore, Tamil Nadu, from August 2023 to April 2024. A total of 100 whole prostatectomy specimens were collected during forensic autopsies of male decedents aged 40-86 years, who had died under various medicolegal causes. Histopathological analysis was performed to identify the presence of latent prostate cancer. Data collected included basic history, cause of death, location of PCa, and Gleason scores.</p><p><strong>Results: </strong>Histopathological examination revealed that 9 out of 100 cases were diagnosed with invasive adenocarcinoma, with Gleason scores of 3 + 3 = 6 or 3 + 4 = 7, primarily in individuals aged over 60. The remaining 91 cases exhibited benign prostatic hyperplasia (BPH). These latent malignancies were more frequently found in individuals over the age of 60 years.</p><p><strong>Conclusions: </strong>This study highlights the role of forensic autopsies in detecting latent prostate cancer that may have gone undiagnosed during life. By providing insight into the frequency and characteristics of prostate cancer in a defined geographic and demographic context, the findings contribute to the understanding of its natural history. The results emphasize the need for age-specific screening strategies and underscore the importance of comprehensive autopsy evaluations in uncovering hidden disease burdens in the population.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"1227-1234"},"PeriodicalIF":2.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144576979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genomic Signatures Correlating With Adverse Pathologic Features in Men Eligible for Active Surveillance.","authors":"Jamie Michael, Eric V Li, Mitch Huang, Nicole Handa, Nalin Kundu, Austin Ho, Hiten D Patel, James A Proudfoot, Sai Kaushik Shankar Ramesh Kumar, Edward M Schaeffer, Elai Davicioni, Ridwan Alam, Ashley E Ross","doi":"10.1002/pros.24924","DOIUrl":"10.1002/pros.24924","url":null,"abstract":"<p><strong>Background: </strong>Genomic biomarkers offer opportunities to improve risk stratification for patients with prostate cancer. We performed a transcriptomic profile of active surveillance (AS)-eligible patients who underwent radical prostatectomy (RP) to understand genomic associations with adverse pathologic features (APF) at RP.</p><p><strong>Methods: </strong>Patients considered AS-eligible (NCCN low-favorable intermediate risk) but proceeded to RP from February 2012 to September 2024 were identified from our prospective institutional database. Outcomes were classified by presence or absence of APF at RP, which was defined as grade group (GG) ≥ 3, pT3b, or pN1 disease. Previously established genomic signatures of interest were compared between the two groups. Scaled multivariable logistic regression was performed to evaluate associations between multiple genomic classification systems and the outcome of APF.</p><p><strong>Results: </strong>There were 184 AS-eligible patients, of whom 153 (83.2%) had favorable intermediate risk disease and 31 (16.8%) had low risk disease. There were 41 patients (22.3%) who had APF at RP. The incidence of favorable intermediate risk disease did not differ between those with and without APF (80.5% vs. 83.9%, p = 0.64). Patients with APF had a higher baseline PSA (5.6 ng/mL vs. 4.9 ng/mL, p = 0.01) and Decipher score (0.55 vs. 0.41, p = 0.004) compared to those without APF. On scaled logistic regression with adjustment for log-transformed PSA, the Decipher score, PTEN loss, activated CD4, and ERG positive rate were significantly associated with APF (OR 1.61, 95% CI 1.11-2.32, p = 0.01). Of ten other previously published genomic classifiers, nine were significantly associated with APF.</p><p><strong>Conclusion: </strong>AS-eligible patients with APF at RP demonstrate differences in gene expression when compared to those without APF. We established that multiple existing genomic classifiers not previously studied in this context demonstrate the ability to predict APF in this patient population. Inclusion of genomics in the risk stratification of AS-eligible patients has the potential to better inform clinical decisions.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"1114-1120"},"PeriodicalIF":2.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12278701/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144334459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Germline Testing for Prostate Cancer Patients: Evidence-Based Evaluation of Genes Recommended by NCCN Guidelines.","authors":"Jianfeng Xu, Jim Lu, Marta Gielzak, S Lilly Zheng, Lucy Lu, Jun Wei, Brandon Cornell, Zhuqing Shi, Qiang Wang, Huy Tran, Valentina Engelmann, Annabelle Ashworth, Kirk Lin, Ashley E Ross, Patrick C Walsh, Catherine Marshall, Jun Luo, William B Isaacs, Brian T Helfand, Christian P Pavlovich","doi":"10.1002/pros.24918","DOIUrl":"10.1002/pros.24918","url":null,"abstract":"<p><strong>Background: </strong>Approximately 50% of prostate cancer (PCa) patients meet the National Comprehensive Cancer Network (NCCN) guidelines for germline testing at diagnosis. However, the selection of genes for testing, their supporting evidence, and clinical interpretation remain poorly understood.</p><p><strong>Methods: </strong>An evidence-based evaluation of the recommended genes was conducted using data from the UK Biobank and Johns Hopkins School of Medicine, including 22,052 PCa patients and 191,055 unaffected controls. Association of germline pathogenic/likely pathogenic (P/LP) variants in each gene was tested using logistic regression, adjusting for age and genetic background.</p><p><strong>Results: </strong>Among the 11 NCCN-recommended PCa-related genes, significant associations (p < 0.0045) were identified between germline P/LP variants of five genes (HOXB13, BRCA2, ATM, CHEK2, and MSH2) and PCa risk. Additionally, BRCA2 and ATM variants were significantly associated with PCa aggressiveness. Of the 19 NCCN-recommended genes related to PARPi sensitivity, consistent evidence supported an enhanced response to PARPi therapy in patients with BRCA2 alterations, with weaker evidence for BRCA1, and limited supporting evidence for the remaining genes. Germline P/LP variants in BRCA2 and BRCA1 were observed in 0.77% and 0.14% of unselected PCa patients, respectively. Notably, no published study specifically assessed the efficacy of germline alterations, which were considerably rarer than somatic mutations.</p><p><strong>Conclusion: </strong>Supporting statistical evidence is available for only a subset of the NCCN-recommended genes for germline testing. This evidence-based analysis may aid urologists-particularly those without specialized genetics training-in understanding germline testing for PCa risk assessment, prognosis, and treatment decision-making in clinical practice.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"1087-1095"},"PeriodicalIF":2.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12278705/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144129615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of Cell-Cycle Proliferation Test, Triple Hit Phenotype, and TMPRSS2-ERG Expression to Evaluate the Risk of Progression in Prostate Cancer Patients Under Active Surveillance.","authors":"Marco Oderda, Giulia Orlando, Giorgio Calleris, Giulia Capella, Luisa Delsedime, Eleonora Duregon, Paola Francia di Celle, Donatella Pacchioni, Ian Marc Bonapace, Zaibunnisa Zaibunnisa, Daniele D'Agate, Gabriele Montefusco, Claudia Filippini, Mauro Papotti, Paolo Gontero","doi":"10.1002/pros.24921","DOIUrl":"10.1002/pros.24921","url":null,"abstract":"<p><strong>Background: </strong>An accurate estimation of progression risk in patients with prostate cancer (PCa) amenable to active surveillance (AS) is still an unmet need. Among available biomarkers, we considered Prolaris cell-cycle progression (CCP) test, \"triple hit\" phenotype (ERG overexpression, PTEN and prostein expression loss) and elevated expression levels of TMPRSS2-ERG gene fusions.</p><p><strong>Methods: </strong>We performed a case-control study, enrolling patients that entered the AS programme at our tertiary referral Institution. Men subsequently undergoing radical prostatectomy for progression were considered as \"cases\", while men still on AS at the end of the follow-up period were labeled as \"controls\". CCP test, triple hit and TMPRSS2-ERG expression analyses were performed on tumoral tissue retrieved from biopsies at enrollment. Their ability to distinguish \"cases\" and \"controls\" was evaluated. According to power analysis, the study required 40 patients.</p><p><strong>Results: </strong>Patients had comparable baseline characteristics. CCP test suggested to continue AS in 75% of controls and to undergo an active treatment in 75% of cases. CCP molecular score (HR 8.5, p = 0.02) was significantly associated with progression in multivariable logistic regression. No significant differences were found in terms of \"triple hit\" or TMPRSS2:ERG expression. IHC analysis was feasible only in 17 patients due to insufficient material.</p><p><strong>Conclusions: </strong>CCP test may be a useful tool to estimate the risk of progression in PCa patients and guide the decision between AS and active treatment. Triple hit phenotype or TMPRSS:ERG fusion status was not associated with progression.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"1104-1113"},"PeriodicalIF":2.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12278703/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144175853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive Genomic Profiling Testing for Castration-Resistant Prostate Cancer in Advanced Elderly Patients: A Single-Center Retrospective Cohort Study.","authors":"Takafumi Fukushima, Keisuke Goto, Yoshinori Nakano, Shinsaku Tasaka, Kyohsuke Iwane, Ryo Tasaka, Kohei Kobatake, Akihiro Goriki, Asuka Toshida, Akiko Abe, Misako Ishihara, Hikaru Nakahara, Masanori Motonaga, Kentaro Tokumo, Yasutoshi Fujii, Hayes Clair Nelson, Hiroaki Niitsu, Shinya Ohara, Yuji Urabe, Wataru Okamoto, Eiso Hiyama, Koji Arihiro, Takao Hinoi, Nobuyuki Hinata","doi":"10.1002/pros.24926","DOIUrl":"10.1002/pros.24926","url":null,"abstract":"<p><strong>Background: </strong>Prostate cancer (PCa) is the second most common solid tumor in men, and its incidence is strongly dependent on age. With the aging global population, this poses a significant medical and sociodemographic issue. As treatment options for castration-resistant prostate cancer (CRPC) expand, the proportion of elderly patients with CRPC is expected to increase. Comprehensive genomic profiling (CGP) testing is becoming increasingly utilized for PCa; however, evidence on age-related outcomes or benefits is limited. This study aimed to evaluate the efficacy of CGP testing in advanced elderly patients with CRPC compared to younger patients.</p><p><strong>Methods: </strong>We conducted a single-center, retrospective cohort study at Hiroshima University, including Japanese men aged ≥ 20 years who underwent CGP testing for CRPC between January 1, 2021, and May 31, 2024. Patients were categorized into the following two groups: the \"advanced elderly group\" (≥ 75 years) and the \"younger group\" (< 75 years). Clinical data were retrospectively extracted from medical records. CGP testing was performed using the FoundationOne® CDx, FoundationOne® Liquid CDx, Gurdant360® CDx, PleSSision Exome, or OncoGuide™ NCC Oncopanel System. Pathogenic alterations were categorized into relevant subgroups. Statistical analyzes were performed to compare patient backgrounds, genomic subgroups, and outcomes between the age groups.</p><p><strong>Results: </strong>Overall, 85 patients (median age: 74 years) were included in the analysis, with 38 and 47 in the advanced elderly and younger groups, respectively. No significant differences were observed in baseline clinical characteristics other than age. CGP testing identified 355 pathogenic variants (140 and 215 in the advanced elderly and younger groups, respectively), with similar distributions of alteration types across the two groups. Among the subgroups, DNA repair and homologous recombination repair-related gene alterations were significantly more frequent in the younger group (p = 0.017) than in the advanced elderly group. Overall survival (OS) did not differ significantly between the age groups. However, patients who received systemic chemotherapy based on CGP testing results had significantly better OS than those who did not receive systemic therapy (p = 0.045). This trend remained significant in the advanced elderly group (p = 0.006).</p><p><strong>Conclusions: </strong>CGP testing appears to offer clinical benefits for patients with CRPC, regardless of age.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"1134-1142"},"PeriodicalIF":2.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12278702/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144267893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"miRNAs Regulating GSTP1 as Potential Diagnostic Biomarkers in Prostate Cancer.","authors":"Shiv Verma, Cheryl L Thompson, Pingfu Fu, Gregory T MacLennan, Sanjay Gupta","doi":"10.1002/pros.70011","DOIUrl":"10.1002/pros.70011","url":null,"abstract":"<p><strong>Background: </strong>Specific and sensitive minimally-invasive biomarker(s) for early detection of prostate cancer is urgently needed to reduce false detection and odds of overtreatment. MicroRNAs (miRNAs) are 19-24-nt noncoding RNAs that regulate gene expression, have emerged as promising blood-based biomarkers due to their frequent dysregulation in cancer.</p><p><strong>Methods: </strong>miRNA levels were quantified in a total of 86 human plasma samples, consisting of 44 prostate cancer patients and 42 individuals with no cancer, using quantitative real-time PCR. Serum PSA and plasma GSTP1 levels were detected by using ELISA assay. The sensitivity and specificity of these miRNAs were evaluated through ROC (Receiver Operating Characteristic) curve analysis.</p><p><strong>Results: </strong>To identify sensitive and specific miRNA biomarkers for prostate cancer, target prediction analysis was performed. This analysis highlighted hsa-miR-133a-3p, hsa-miR-144-3p, hsa-miR-153-3p, and hsa-miR-590, which regulate glutathione S-transferase P1 (GSTP1), a gene epigenetically silenced in all stages of prostate cancer. The absolute expression levels of these miRNAs were quantified in plasma samples from 44 prostate cancer patients and 42 noncancer individuals. Sensitivity and specificity were assessed using ROC curve analysis. Binary logistic regression ROC analysis revealed that hsa-miR-133a-3p and hsa-miR-153-3p demonstrated exceptional specificity and sensitivity for prostate cancer detection, with p values of < 0.0001 and 0.0003, outperforming PSA levels. Further validation in an independent data set of 64 noncancer individuals and 26 prostate cancer patients confirmed significant differences in hsa-miR-133a-3p and hsa-miR-153-3p expression between the groups. The two-miRNA panel exhibited high diagnostic accuracy, with an area under the curve between 0.98 and 1.0.</p><p><strong>Conclusions: </strong>These results suggest that the two-miRNA panel represents a significant advancement over PSA testing and shows strong potential as a reliable blood-based diagnostic tool for prostate cancer detection.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"1235-1244"},"PeriodicalIF":2.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144602216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}